Global Head and Executive Director, International Commercial Launch and Market Access
- Employer
- BioNTech SE (Nasdaq: BNTX)
- Industry
- Biotechnology / Biopharmaceuticals / Immunotherapy & Infectious Diseases Vaccines
- Location
- Mainz or Frankfurt am Main, Hesse, Germany
- Country
- Germany
- Work arrangement
- Hybrid (executive leadership presence in Frankfurt with global travel)
- Employment type
- Full-Time Executive
- Seniority
- Executive Director / Global Function Head
- Department
- Global Commercial Operations & Market Access
- Compensation
- USD 520,000 – 680,000 per Year
- Application status
- Accepting applications
- Closing date
- 2026-11-26
Your application is received by Westbridge for review. We do not automatically forward materials to an employer.
About the role
The executive holds enterprise accountability for integrated launch readiness, HTA strategy, payer value proposition architecture, public-private partnership frameworks, and cross-regional commercial execution. The role addresses complex reimbursement environments, divergent European and emerging-market regulatory pathways, and competitive vaccine and oncology landscapes to ensure optimal pricing corridors, accelerated time-to-market access, and durable commercial adoption. The position serves as the primary commercial bridge connecting Global Clinical Development, Regulatory Affairs, Medical Affairs, HEOR, Supply Chain, and Regional General Managers. Approx. 35–45% international travel.
Company overview
BioNTech SE, headquartered in Mainz, Germany (document also references Munich), is a globally recognized next-generation immunotherapy company pioneering novel therapies and vaccines for cancer and infectious diseases. Founded in 2008 and Nasdaq-listed, BioNTech combines computational discovery, mRNA technology platforms, cell therapies, bispecific antibodies, and targeted small-molecule and antibody-drug conjugate modalities. Its portfolio includes the global COVID-19 vaccine franchise (Comirnaty, partnered with Pfizer), late-stage oncology assets (e.g., autogene cevumeran, BNT111, BNT327), and prophylactic infectious disease vaccine candidates (malaria, tuberculosis, mpox, shingles). The company is scaling its wholly owned international commercial infrastructure to support independent launches and reduce reliance on single-product revenues.
Key responsibilities
Lead end-to-end international launch planning and commercial readiness across infectious disease and oncology portfolios, establishing standardized launch excellence frameworks from Phase IIb/III transition through post-launch lifecycle expansion.
Define and govern global pricing corridors, innovative contracting models (outcome-based agreements, risk-sharing schemes, volume-tiered tender frameworks), and reference-pricing mitigation strategies across European and emerging international markets.
Direct commercial expansion and public-health market entry strategies across Emerging Europe, Eurasia, and high-growth territories, leveraging expertise in NITAGs, supranational procurement bodies, and government tender ecosystems.
Partner with Global HEOR and Medical Affairs to design payer-relevant clinical trial endpoints, real-world evidence generation plans, and EU Joint Clinical Assessment (JCA) dossiers substantiating clinical differentiation and economic value.
Guide regional commercial leads and country market access directors to align local launch sequencing, resource deployment, and commercial KPIs with corporate revenue targets.
Lead executive-level negotiations and institutional partnerships with Ministries of Health, national public health agencies, supranational health organizations, and tender authorities to secure multi-year supply and access agreements.
Represent BioNTech's international commercial and market access interests within co-development and co-commercialization alliances, ensuring unified brand positioning and disciplined financial governance.
Partner with Finance, Corporate Strategy, and Global Supply Chain on multi-year revenue forecasts, demand planning, and lifecycle extension strategies.
Recruit, mentor, and lead a multidisciplinary team of international launch directors, market access strategists, and regional commercial specialists across Mainz, Frankfurt, and key international markets.
Candidate profile
Minimum 15 years of progressive leadership experience in global biopharmaceutical/biotechnology, with substantial senior accountability in commercial operations, product launch, and market access. Demonstrated track record in vaccines and/or specialty biopharmaceuticals across European and emerging international markets. Proven mastery of European HTA systems, national reimbursement frameworks, public health immunization programs, and complex government/institutional tender processes. Extensive experience leading multi-country commercial teams, managing cross-functional matrices, and influencing C-suite stakeholders. Bachelor's degree in Life Sciences, Pharmacy, Medicine, Economics, Business Administration, or related discipline required. Executive fluency in English; German, French, and Turkish proficiency advantageous.
Required qualifications
Bachelor's degree in Life Sciences, Pharmacy, Medicine, Economics, Business Administration, or a related discipline.
Minimum 15 years of progressive leadership experience within global biopharmaceutical or biotechnology, including substantial senior leadership accountability in commercial operations, product launch, and market access.
Demonstrated track record leading commercial strategy and market access for vaccines and/or specialty biopharmaceuticals across European and emerging international markets.
Proven mastery of European HTA systems, national reimbursement frameworks, public health immunization programs, and complex government/institutional tender processes across Emerging Europe and international markets.
Extensive experience leading multi-country commercial teams, managing cross-functional matrices, and influencing senior C-suite stakeholders in multinational biopharmaceutical organizations.
Preferred qualifications
MBA, PhD, PharmD, MD, or Master's in Health Sciences, Public Health, or International Business. Direct commercial launch or market access experience in immuno-oncology, precision medicine, or specialty biologics alongside infectious disease vaccines. Prior leadership navigating co-commercialization partnerships and building commercial launch infrastructure within growth, R&D-driven biotechnology enterprises. Multilingual proficiency (English, German, French, Turkish).
Compensation & benefits
Salary: USD 520,000 – 680,000 per Year
Total target compensation $520,000–$680,000 USD per annum (base salary estimated $340,000–$410,000 USD equivalent; annual short-term incentive 25%–35% of base; annual LTI grant of RSUs and/or PSUs). Benefits include statutory and supplemental private healthcare, company-sponsored executive pension and retirement contributions, executive disability and life insurance, relocation and tax advisory support, executive mobility allowance, and 30 days annual paid leave. Note: the document contains an internal inconsistency page 1 states a flat $680,000 total target compensation, while Sections 1 and 16 state $520,000–$680,000.
Work arrangements
Arrangement: Hybrid (executive leadership presence in Frankfurt with global travel)
Location: Mainz or Frankfurt am Main, Hesse, Germany
Hybrid executive model combining regular on-site leadership presence in Frankfurt/Mainz with flexible remote work when not traveling. Primary work location: BioNTech SE headquarters in Mainz or the Frankfurt am Main regional hub (seamless rail/air connectivity via Frankfurt Airport). Approximately 35%–45% international travel across European capitals, Emerging European markets, alliance partner hubs, and major international medical and payer congresses. Full executive relocation assistance, immigration/work permit sponsorship (if required), housing transition support, and cross-border tax consultation provided for candidates relocating to the Rhine-Main region.
Reporting structure
Reporting line: Reports to Chief Commercial Officer (CCO) or Senior Vice President, Global Commercial Operations
Department: Global Commercial Operations & Market Access
Application instructions
Submit an updated executive CV highlighting senior leadership experience in international pharmaceutical/vaccine commercial, launch excellence, and market access; documented track record navigating European HTA frameworks, pricing governance, and emerging-market public procurement/tender environments; and scale of teams, budgets, and multi-country commercial portfolios. Candidates should also be prepared to discuss three position-specific executive documents: (1) International Launch Strategy and EU HTA Readiness Framework; (2) Emerging Markets Vaccine Tendering & Sovereign Procurement Dossier; (3) International Commercial Portfolio Valuation & Payer Value Proposition Structure. Initial confidential discussions are conducted by Westbridge Search prior to formal panel interviews in Mainz/Frankfurt. Contact: Westbridge Search (retained intermediary).
Independent analysis
This is a high-visibility, build-and-lead mandate at a genuine inflection point for BioNTech — the shift from a single blockbuster vaccine franchise to a multi-product commercial enterprise is one of the more consequential transitions in European biotech, and this role sits directly on that fault line. The compensation ($520k–$680k TTC) is competitive for a Global Function Head in the German biopharma market but sits below US-based equivalents for comparable scope, which is consistent with European executive benchmarks; the equity component is where the real upside lies given BioNTech's pipeline. The document's internal inconsistencies (headquarters stated as both Munich and Mainz; flat $680k vs. $520k–$680k range; "Marketing Access" vs. "Market Access" in the title) suggest a hastily assembled or templated mandate and warrant clarification with Westbridge before proceeding. The three required "specialised documents" are unusually demanding for an initial application stage and function as a de facto work-sample screen candidates should treat them as substantive deliverables, not formalities. The 15–20% time-to-market acceleration KPI is ambitious but plausible for a well-resourced launch organization. Overall: a strong fit for a commercially seasoned vaccine/oncology market access leader with Emerging Europe tender depth and German-language capability; less suitable for pure oncology or US-centric profiles.
Interested in this role?
Westbridge reviews role enquiries and responds with relevant information about the opportunity and its application process.
Ask about this role →More opportunities
Loading roles…